NSE: MANKIND | BSE: 543904

Expensive Performer

Download real time

2589.50 -9.50 (-0.37%)

36.21% Gain from 52W Low

715.6K NSE+BSE Volume

NSE 24 Jul, 2025 3:31 PM (IST)

106,876.1

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Mankind Pharma Ltd. is on 31 Jul 2025 for the purpose of Quarterly Results & Interim Dividend See details

Mankind Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MANKIND, BSE:543904 Mankind Pharma Ltd.

Mankind Pharma Ltd.

20 Apr 2023

2589.50

-0.37%

IPO Note - Mankind Pharma Limited 20042023

IPO Note: Mankind Pharma Ltd.

HDFC Securities

Issue Snapshot: Issue Open: Apr 25 Apr 27, 2023 Price Band: Rs. 1026 1080 *Issue Size: 4326.36 cr (Entirely Offer for Sale of 40,058,844 eq sh) Reservation for: QIB upto 50% eq sh Non-Institutional atleast 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail atleast 35% eq sh Face Value: Rs 1 Book value: Rs 178.38 (December 31, 2022) Bid size: - 13 equity shares and in multiples thereof 100% Book built Issue IPO Note - Mankind Pharma Limited

Mankind Pharma Ltd. is trading above all available SMAs

Mankind Pharma Ltd.

20 Apr 2023

2589.50

-0.37%

Domestic leader gears up for listing

IPO Subscribe: Mankind Pharma Ltd.

Centrum Broking

Mankind is a well?known player in the domestic pharma market (with 97.6% of sales), and is 4th largest in terms of sales and 3rd largest in terms of sales volume as on Dec’22 MAT. About 36 brands in the Pharma business, which has sales over Rs500mn, with strong brand positioning. In the consumer segment, it has leading brands i.e Manforce, Prega News, Unwanted?72, which are having significant market share in their
respective categories.